Detail of "71636-61-8"

Reference

Dopaminergic control of sleep-wake states

All Rights Reserved. Dopaminergic control of sleep-wake states. [Erratum to document cited in CA]. Dzirasa, Kafui; Ribeiro, Sidarta; Costa, Rui M.; Santos, Lucas M.; Lin, Shih-Chieh; Grosmark, Andres; Sotnikova, Tatyana D.; Gainetdinov, Raul R.; Caron, Marc G.; Nicolelis, Miguel A. L. 71636-61-8 and 51-61-6 are cas registry numbers of chemicals which are used as reagents here. (Department of Neurobiology, Duke University Medical Center, Durham, NC 27710, USA). Journal of Neuroscience, 26(47), v (English) 2006 Society for Neuroscience. CODEN: JNRSDS. ISSN: 0270-6474. DOCUMENT TYPE: Journal CA Section: 2 (Mammalian Hormones) The third author, Rui M. Costa, was incorrectly given as "Rui Costa". .

Effects of dopamine D1 ligands on eye blinking in monkeys: Efficacy, antagonism, and D1/D2 interactions

Effects of dopamine D1 ligands on eye blinking in monkeys: Efficacy, antagonism, and D1/D2 interactions. Jutkiewicz, Emily M.; Bergman, Jack (Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA). Journal of Pharmacology and Experimental Therapeutics, 311(3), 1008-1015 (English) 2004 American Society for Pharmacology and Experimental Therapeutics. CODEN: JPETAB. ISSN: 0022-3565. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 2 Dopamine D1 ligands have been classified and ordered according to efficacy in both in vitro and in vivo studies. In the present expts., dopamine D1 ligands reported to differ in in vitro efficacy were evaluated for efficacy-related effects on eye blinking in squirrel monkeys. Addnl. comparisons were made with the effects of D2 receptor agonists and indirect dopamine agonists. 537-46-2 and 71636-61-8 are cas registry numbers of chemicals which are used as reagents here. The results show that D1 agonists increased eye blinking in an efficacy-related manner, whereas the D1 receptor blocker SCH 39166 only decreased rates of eye blinking. D1 high-efficacy agonists induced rates of eye blinking that were 2- to 3-fold greater than obsd. with dopamine D2 agonists and indirect agonists. In drug combination expts., increases in eye blinking induced by the D1 high-efficacy agonist R-(+)-6-Br-APB [R-(+)-6-bromo-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-b enzazepine hydrobromide] were antagonized by both the D1 antagonist SCH 39166 and the lower efficacy agonist SKF 83959, consistent with dopamine D1 receptor mediation of these behavioral effects. The dopamine D2 agonist (+)-PHNO [(+)-N-propyl-hydroxynaphthoxazine], which selectively activates dopamine D2 receptors, also attenuated D1 agonist-induced increase in eye blinking, suggesting that D2 receptor actions may inhibit D1-mediated increases in eye blinking. Overall, eye blink rate appears to be a robust behavioral measure that can be used to measure changes in dopaminergic D1 signaling and as a functional assay of agonist efficacy at dopamine D1 receptors. .